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Abstract The primary site in PHAS-I for phosphorylation by
protein kinase CK2 in vitro was identified as Ser111. A relatively
small amount of phosphorylation of Ser99 was also detected, and
mutating Ser99 to Ala in PHAS-I slightly decreased phosphor-
ylation by CK2 in vitro. In contrast, mutating Ser111 to Ala
almost abolished phosphorylation, confirming Ser111 as the
preferred site for CK2. Phosphorylation of Ser111 did not
decrease binding of PHAS-I to eIF4E, and results of peptide
mapping experiments with PHAS-I immunoprecipitated from
32P-labeled adipocytes indicated that Ser111 was not phosphory-
lated in cells. These results support the conclusion that CK2 is
not involved in the control of PHAS-I.
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1. Introduction
PHAS-I (also known as 4E-BP1) regulates mRNA trans-
lation initiation by controlling the availability of eIF4E [1^
3]. This initiation factor is responsible for recognition of the
mRNA cap (m7GpppN, where N is any nucleotide), which is
found at the 5P-end of almost all eukaryotic mRNAs. Non-
phosphorylated PHAS-I binds tightly to eIF4E and prevents
eIF4E from binding to eIF4G, a large sca¡olding protein that
also binds eIF4A and eIF3. When phosphorylated in the ap-
propriate site(s), PHAS-I dissociates from eIF4E. This allows
eIF4E to bind eIF4G to form a complex needed for e⁄cient
binding and/or scanning by the 40S ribosomal subunit. Insulin
and growth factors increase mRNA translation by promoting
the phosphorylation of PHAS-I [1^3]. In addition, the phos-
phorylation of PHAS-I may contribute to the mitogenic ac-
tions of growth factors, as increasing eIF4E has been shown
to have a potent mitogenic e¡ect, at least in some cell types
[4,5]. For these reasons it is important to identify the protein
kinases that mediate the phosphorylation of PHAS-I in cells.
Rat adipocytes express very high levels of PHAS-I and are
exquisitely responsive to insulin [6]. Five phosphorylation
sites, all having a (S/T)P motif, have been identi¢ed in
PHAS-I from adipocytes [7]. The ¢nding that the e¡ect of
insulin on increasing phosphorylation of PHAS-I was attenu-
ated by rapamycin implicated mTOR in the control of the
protein [8^10]. In recent studies all ¢ve (S/T)P sites were found
to be phosphorylated by mTOR in vitro [11,12]. While it is
clear that mTOR has an important role in controlling PHAS-
I, there is reason to suspect that other kinases contribute, as
rapamycin does not abolish the e¡ect of insulin on increasing
the phosphorylation of PHAS-I [10,13].
Protein kinase CK2, also known as casein kinase II, was the
¢rst protein kinase found to phosphorylate PHAS-I in vitro
[14]. CK2 has the interesting property of phosphorylating the
eIF4E-bound form of PHAS-I more rapidly than it phosphor-
ylates free PHAS-I [13,15]. Insulin has been reported to in-
crease the activity of CK2 in rat adipocytes [14], and it has
been suggested that phosphorylation in the CK2 site primes
PHAS-I in the eIF4E complex for phosphorylation by other
protein kinases [3]. CK2 prefers an acidic residue immediately
COOH terminal (+1 to +3) to the phosphorylated Ser/Thr
residue [16,17]. PHAS-I contains four sites that meet this min-
imal consensus requirement [18]. The objectives of the present
study were to identify sites in PHAS-I phosphorylated by
CK2 in vitro and to determine whether the sites were phos-
phorylated in response to insulin in rat adipocytes.
2. Materials and methods
2.1. Preparation of recombinant PHAS-I proteins
Histidine-tagged PHAS-I ([H6]PHAS-I) and mutant proteins were
puri¢ed as described previously [19]. cDNAs encoding mutant PHAS
proteins were generated using the polymerase chain reaction with
mutagenic oligonucleotide primers and rat PHAS-I cDNA as template
[18]. The primers were designed to yield products having BamHI sites
at both the 5P and 3P ends. Ser99, Ser111, and Ser99 plus Ser111 were
mutated by converting the respective Ser codons to Ala codons in the
3P primers. After ampli¢cation (20 cycles), the products were puri¢ed,
cut with BamHI, and inserted into the BamHI site of pET-14b (No-
vagen). cDNA clones used to express proteins were sequenced to be
sure that no unwanted mutations were present.
2.2. Puri¢cation of protein kinase CK2
CK2 was puri¢ed by a method similar to that described by Hath-
away and Traugh [20]. Brie£y, rabbit skeletal muscle (500 g, New
Zealand White) was homogenized in Bu¡er A (1 mM EDTA, 1 mM
DTT, 50 mM MOPS, pH 7.5) containing 1 mM benzamidine,
0.5 mM phenylmethylsulfonyl £uoride, and 0.1 Wg/ml aprotinin. The
homogenate was centrifuged at 11 000Ug for 30 min, and the super-
natant was loaded onto a Fast Flow Q Sepharose column (200 ml)
that had been equilibrated in Bu¡er A. Proteins were eluted with a 3-l
linear gradient of NaCl (from 0 to 1 M) in Bu¡er A and fractions
(15 ml) were collected. CK2 activity was measured (described later)
and peak fractions were pooled, dialyzed against Bu¡er A plus
250 mM NaCl, and applied to a phosphocellulose column (40 ml)
that had been equilibrated in the dialysis bu¡er. The column was
washed with 10 volumes of Bu¡er A plus 450 mM NaCl. CK2 was
eluted with Bu¡er A plus 800 mM NaCl. Peak fractions containing
the kinase were pooled and dialyzed against Bu¡er B (1 mM EDTA,
1 mM DTT, 15 mM potassium phosphate, pH 6.8). The sample was
applied to a 1-ml hydroxylapatite (Bio-Rad) column that had been
equilibrated in Bu¡er B. The column was washed with 10 volumes of
Bu¡er B before CK2 was eluted with a 150-ml linear gradient (from
15 mM to 300 mM) of sodium phosphate. Peak fractions were pooled,
dialyzed against Bu¡er B plus 1 M NaCl, and stored at 4‡C.
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2.3. Measurements of CK2 activity
Samples (10 Wl) were added to reaction mixtures (20 Wl) that con-
tained 150 mM NaCl, 7.5 mM MgCl2, 300 mM [Q-32P]ATP (V1000
cpm/pmol), 100 WM RRDDDSDDD, and 10 mM HEPES, pH 7.4.
After incubating at 23‡C for 20 min, the reactions were stopped by
adding 20 Wl of 1% phosphoric acid. The samples were then spotted
onto squares (1 cm) of phosphocellulose paper (Whatman P81), which
were washed with phosphoric acid as described previously [21].
2.4. Peptide mapping
Samples of 32P-labeled PHAS-I were digested with lysyl endopepti-
dase (Wako) and peptides were resolved by reverse phase HPLC as
described previously [7]. For cleavage with CNBr, samples of 32P-
labeled PHAS-I were dried under vacuum (Speedvac, Savant), then
dissolved in 100 Wl 70% formic acid. After adding 1 mg CNBr to each,
the samples were incubated for 15 h at 21‡C. The samples were then
dried under vacuum, dissolved in 200 Wl H2O, taken to dryness again,
and dissolved in either 0.1% tri£uoroacetic acid for HPLC analyses or
in SDS-sample bu¡er for SDS-PAGE [22].
2.5. Electrophoretic analyses
Phosphoamino acid analysis was conducted using the method of
Geer et al. [23]. Far-Western analysis to assess binding of PHAS-I
to eIF4E was performed as described previously [24]. Brie£y, PHAS-I
proteins were subjected to SDS-PAGE [22], then transferred to Im-
mobilon (Millipore) and incubated with a 32P-labeled FLAG-eIF4E
fusion protein. After washing the membranes, the amount of 32P-
labeled FLAG-eIF4E bound was determined by autoradiography.
2.6. Amino acid sequencing
The 32P-labeled peptides generated by phosphorylating recombinant
PHAS-I with [Q-32P]ATP and CK2 were identi¢ed by using a vapor
phase amino acid sequencer (Applied Biosystems Procise 494). Phos-
phorylated residues within phosphopeptides were located by determin-
ing the cycles in which 32P was released when samples were subjected
to sequential Edman degradation under conditions that optimize re-
covery of 32P [25].
2.7. Incubation of adipocytes and immunoprecipitation of PHAS-I
Rat adipocytes were isolated from male rats (Wistar, 120 g), incu-
bated with 32Pi and treated with insulin exactly as described previ-
ously [7]. [32P]PHAS-I was immunoprecipitated from extracts by using
an antibody directed against the COOH terminal region of PHAS-I
[26].
3. Results
3.1. Phosphorylation of PHAS-I by CK2 does not inhibit
eIF4E binding
Incubating recombinant PHAS-I for increasing times with
puri¢ed CK2 and Mg-[Q-32P]ATP resulted in a progressive
incorporation of phosphate into the PHAS-I protein (Fig.
1). The stoichiometry approached 0.5 mol phosphate per
mol PHAS-I after 2 h (Fig. 1). 32P-Labeled FLAG-eIF4E
binding to PHAS-I, assessed by far-Western blotting, was
not decreased by the incubation with CK2, even after 2 h
(Fig. 1).
3.2. Identi¢cation of phosphorylation sites
The results in Fig. 1 do not exclude CK2-mediated phos-
phorylation in the control of PHAS-I, as the sites phosphory-
lated by the kinase might modulate the e¡ect of other phos-
phorylation sites on eIF4E binding. Therefore, experiments
were performed to identify the sites in PHAS-I that were
phosphorylated by CK2 and to determine whether these sites
were phosphorylated in cells.
Thr84, Ser99, Ser100, and Ser111 meet the minimal consensus
requirements for phosphorylation by CK2 [16]. As a ¢rst step
in determining which of these sites was phosphorylated, a
sample of PHAS-I was subjected to acid hydrolysis and phos-
phoamino acids were separated by high voltage electrophore-
sis at pH 3.5. Phosphoserine was the only phosphoamino acid
detected (Fig. 2A, inset). Therefore, Thr84 could be eliminated
as a site of phosphorylation by CK2.
To identify the phosphorylated Ser residues, PHAS-I was
cleaved with CNBr. When samples were subjected to reverse
phase HPLC to resolve peptides, a peak of 32P eluting at
approximately 40% acetonitrile was observed (Fig. 2A). Ami-
no acid sequencing indicated that the phosphopeptide in this
peak resulted from cleavage of PHAS-I at Met90 (Fig. 2B).
Although the peptide was sequenced through only 8 cycles,
the predicted phosphorylated fragment extends to Met115.
Thus, the fragment most likely contained all three Ser residues
that were candidates for phosphorylation by CK2. In a sepa-
rate sequencing run, the release of 32P at each cycle of Edman
degradation was determined. A surge of 32P release was de-
tected at cycle 9 (Fig. 2B). 32P release in subsequent cycles
then declined rapidly. These results indicate that Ser99 was a
site of phosphorylation, although we cannot exclude the pos-
sibility that there was a relatively small amount of phosphate
in Ser100. However, the total amount of 32P released through
cycle 12 represented a very small fraction of the 32P applied to
the sequencer, suggesting that the phosphorylated CNBr pep-
tide contained another phosphorylated residue. Through the
process of elimination, this site would most likely be Ser111.
Incubating PHAS-I with lysyl endopeptidase cleaves at
Lys103 to generate a fragment containing Ser111, which is lo-
cated near the COOH terminus of the protein [18]. This frag-
ment was the major phosphopeptide from CK2-phosphory-
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Fig. 1. E¡ect of increasing time of incubation with CK2 on PHAS-I
phosphorylation and eIF4E binding. Samples of [H6]PHAS-I (10 Wg)
were incubated at 23‡C with 10 milliunits/ml CK2 (where 1 unit =
1 nmol phosphate incorporated into RRDDDSDDD in 1 min) in
reaction mixtures (160 Wl each) containing 150 mM NaCl, 1 mM
dithiothreitol, 10 mM MgCl2, 50 mM Tris-HCl (pH 7.5), and either
300 WM ATP or 300 WM [Q-32P]ATP (850 cpm/pmol). Samples
(15 Wl) were removed after increasing times, added to SDS-sample
bu¡er (20 Wl), and subjected to SDS-PAGE. 32P incorporation (mol/
mol [H6]PHAS-I) was determined by scintillation counting of gel
slices containing [H6]PHAS-I. To assess eIF4E binding, proteins
from samples incubated with unlabeled ATP were electrophoretically
transferred to an Immobilon P membrane, which was then incu-
bated with 32P-labeled FLAG-eIF4E fusion protein (200 000 cpm/
ml) as described previously [24]. The relative amounts of 32P-labeled
FLAG-eIF4E bound were determined by optical density scanning of
an autoradiogram. The results are expressed as percentages of the
32P-labeled FLAG-eIF4E bound to [H6]PHAS-I that was not ex-
posed to CK2.
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lated PHAS-I. It eluted from the reverse phase column in a
sharp peak at 53 min (Fig. 3A), and its identity was estab-
lished by amino acid sequencing (Fig. 3B). The surge in 32P
release occurred in cycle 7 (Fig. 3B), indicating that Ser111 was
the phosphorylated residue.
To investigate further the phosphorylation of Ser99 and
Ser111 by CK2, mutant PHAS-I proteins were prepared. As
expected, CK2 introduced almost no 32P into the PHAS-I
protein in which both Ser99 and Ser111 had been mutated to
Ala (Fig. 4). Changing Ser99 to Ala had a relatively small
e¡ect on the phosphorylation of PHAS-I, supporting the con-
clusion that Ser99 is not a preferred site of phosphorylation by
CK2. In contrast, mutating Ser111 markedly decreased PHAS-
I phosphorylation (Fig. 4), con¢rming the assignment of
Ser111 as the major site of phosphorylation.
3.3. Ser111 is not phosphorylated in rat adipocytes
To determine whether Ser111 was phosphorylated in fat
cells, samples of PHAS-I phosphorylated in vitro by CK2
and of PHAS-I immunoprecipitated from 32P-labeled rat adi-
pocytes were digested with lysyl endopeptidase and the result-
ing phosphopeptides were resolved by reverse phase HPLC
(Fig. 5). The antibodies used immunoprecipitate both free
and eIF4E-bound forms of PHAS-I [26], as well as PHAS-I
phosphorylated in vitro by CK2 (Fadden, Haystead, and
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Fig. 3. Identi¢cation of Ser111 as the preferred site of phosphoryla-
tion by CK2. A: [H6]PHAS-I was phosphorylated by incubation
with [Q-32P]ATP and CK2 (1 unit/ml) at 23‡C for 90 min. The pro-
tein was then digested with lysyl endopeptidase and the resulting
32P-labeled phosphopeptides were resolved by reverse phase HPLC.
The amount of 32P found in each fraction is presented. B: The ma-
jor 32P-labeled fragment obtained after lysyl endopeptidase digestion
of PHAS-I was puri¢ed by reverse phase HPLC. The amino acid se-
quence of the peptide and amount of 32P released in each cycle are
presented as described in the legend to Fig. 2.
Fig. 2. Identi¢cation of Ser99 as a minor phosphorylation site CK2.
A: [H6]PHAS-I (25 Wg) was phosphorylated by incubation with
[Q-32P]ATP and CK2 (1 unit/ml) at 23‡C for 90 min. The protein
was then cleaved with CNBr and the resulting fragments were
resolved by reverse phase HPLC. Results represent the amount of
32P recovered in each fraction. For phosphoamino acid analysis,
[H6]PHAS-I was phosphorylated by incubating with CK2 and
[Q-32P]ATP for 1 h at 23‡C. The phosphorylated protein was puri-
¢ed by SDS-PAGE, then subjected to partial acid hydrolysis (5.7 N
HCl for 1 h at 110‡C). Phosphoamino acids were resolved by elec-
trophoresis at pH 3.5. The positions of standards are indicated on
the autoradiogram presented in the inset. B: The 32P-labeled CNBr
fragment was puri¢ed by reverse phase HPLC and subjected to
12 cycles of sequential Edman degradation. The amino acid sequence
obtained is presented above the corresponding sequence (shown in
italics) encoded by PHAS-I cDNA. In a separate sequencing run,
the amount of 32P released in each cycle was determined. Results
are expressed as percentages of the total 32P loaded.
Fig. 4. Comparison of the rates of phosphorylation of PHAS-I and
mutant PHAS-I proteins by CK2. PHAS proteins (10 Wg each) were
incubated with CK2 for increasing times as described in the legend
to Fig. 1. The relative amounts of 32P incorporated into the proteins
were determined and are expressed as percentages of the maximum
incorporation observed with [H6]PHAS-I.
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Lawrence, unpublished observations). With the CK2-phos-
phorylated sample, the major peak containing Ser111 eluted
between two peaks, previously designated LE-P2 and LE-P3
[7], from the adipocyte PHAS-I. LE-P2 contains a peptide
phosphorylated in Ser64 ; LE-P3 contains peptides phosphory-
lated in Ser36, Ser45, and Ser82. A relatively small peak from
the CK2 sample eluted in the position of LE-P2. This peak
presumably contains Ser99, which is found in the same lysyl
endopeptidase peptide as Ser82 [7].
The absence of a peak of 32P corresponding to the Ser111
peptide in PHAS-I from 32P-labeled adipocytes implies that
Ser111 was not phosphorylated (Fig. 5). However, the reten-
tion time of the Ser111 peptide from adipocytes could di¡er
from that of the recombinant peptide if the COOH terminus
of PHAS-I was modi¢ed in cells. To address this issue, adi-
pocyte PHAS-I was phosphorylated by incubating heat-
treated extracts of fat cells [18] with CK2 and [Q-32P]ATP.
Immunoprecipitation of the 32P-labeled PHAS-I followed by
digestion with lysyl endopeptidase yielded a single 32P-labeled
phosphopeptide that eluted from the reverse phase column in
exactly the same position as the Ser111 peptide from recombi-
nant PHAS-I (Fadden, Haystead, and Lawrence, unpublished
observations). Thus, there does not seem to be a COOH ter-
minal modi¢cation that alters the retention time of the Ser111
peptide. Moreover, even if such a modi¢cation did exist, 32P
should still be released in the seventh cycle when the Ser111
peptide was subjected to sequential Edman degradation. For
this reason, our previous ¢nding that none of the phospho-
peptides derived from lysyl peptidase digestion of PHAS-I
from 32P-labeled adipocytes produced a surge in 32P release
in cycle 7 provides further support for the conclusion that
Ser111 was not phosphorylated in adipocytes [7].
4. Discussion
Ser111 is the preferred site in PHAS-I for phosphorylation
by CK2. This site is located near the COOH terminus of the
protein, and it may be more accessible to the kinase than the
other 3 sites that ¢t the minimal consensus for phosphoryla-
tion by CK2. Also, Ser111 is positioned just downstream of a
pair of Glu residues [18]. Although an Asp/Glu residue in the
+3 position is a strong determinant for phosphorylation by
CK2, acidic residues on the NH2 terminal side exert a positive
in£uence [16,17]. Thus, the more acidic environment of Ser111
and its location near the COOH terminus of PHAS-I may
explain why it is preferentially phosphorylated by the kinase.
Insulin has been reported to activate CK2 in rat adipocytes
[14], and PHAS-I is clearly phosphorylated by the kinase in
vitro. Moreover, CK2 has been shown to e⁄ciently phosphor-
ylate PHAS-I when the protein is bound to eIF4E [13,15]. In
this respect CK2 di¡ers from MAP kinase, which phosphor-
ylates PHAS-I at a relatively slow rate when PHAS-I is bound
to eIF4E [10,13]. Based on these ¢ndings it was logical to
propose that phosphorylation of PHAS-I in the CK2 site
primes PHAS-I in the complex with eIF4E for phosphoryla-
tion by other kinases [3]. However, the absence of phosphate
in Ser111 in PHAS-I immunoprecipitated from rat adipocytes
seems inconsistent with a role of this site in cells.
eIF4E is also controlled in 3T3L1 adipocytes by PHAS-II
(also known as 4E-BP2) [6], a protein having approximately
60% amino acid sequence identity to PHAS-I [24]. PHAS-II
contains neither a Ser nor Thr in the position corresponding
to Ser111 in PHAS-I [6,24]. Consistent with the identi¢cation
of Ser111 as the preferred site for CK2 in PHAS-I, PHAS-II is
not phosphorylated by the kinase in vitro [15]. However, like
PHAS-I, non-phosphorylated PHAS-II binds tightly to eIF4E
[24], and when phosphorylated via the mTOR signaling path-
way in response to insulin, PHAS-II dissociates from eIF4E
[6]. The fact that PHAS-II is regulated even though it does
not possess the equivalent of Ser111 provides additional sup-
port for the argument that Ser111 phosphorylation is not
needed for the control of PHAS-I by insulin.
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